Scientist I Structural Biology, Lead Discovery

This job is no longer active. View similar jobs.

POST DATE 8/24/2016
END DATE 11/2/2016

Nurix, Inc. San Francisco, CA

San Francisco, CA
AJE Ref #
Job Classification
Full Time
Job Type
Company Ref #
Entry Level (0 - 2 years)


We are seeking a highly skilled and motivated Scientist with expertise in Structural Biology to join Nurix s Discovery team. Nurix is devoted to unlocking the therapeutic potential of the ubiquitin proteasome system (UPS) in the areas of oncology and immuno-oncology, by utilizing the mechanistic and structural insights to guide drug discovery efforts. The successful candidate will support structural biology efforts for Nurix s discovery programs. Also, this person will play a key role in impacting the drug discovery process through conceiving and generating critical data and will be an important member of the project team. This individual will work closely with an experienced team of interdisciplinary scientists and have regular opportunities present to the project team and senior management. The ideal candidate will be highly self-driven, resourceful, very organized and focused, and enjoy working in a dynamic team environment

Nurix, Inc. is a science-minded yet goal-oriented organization that is focused on bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein stabilization and degradation, a function vital to the healthy life of a cell, uncovering therapeutic opportunities in multiple disease areas. The Nurix scientific team has established an innovative drug discovery platform to enable the discovery of selective small molecule inhibitors or activators of the UPS, enabling the discovery of new class of drugs that can restore normal cellular homeostasis. In September 2015, Nurix entered into a multiyear collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis. The collaboration encompasses oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures, The Column Group, and a multi-year strategic collaboration with Celgene. The company is based in San Francisco, California.